导航不良免疫刺激:临床研究人员的实用指南
Juliette A van den Noort1,2, Anouk C Meijs1,2, Naomi B Klarenbeek1,2
1Centre for Human Drug Research, Leiden, the Netherlands.
British journal of clinical pharmacology
|September 13, 2025
概括
负面免疫刺激 (AIS) 复杂化了药物开发. 早期试验中的标准化生物标志物分析有助于管理AIS,了解药物机制,并提高临床试验的效率.
科学领域:
- 药理学 药理学是指药理学的学科.
- 临床试验管理 临床试验管理
- 免疫毒理学 免疫毒理学
背景情况:
- 药物开发面临的挑战是复杂的产品导致不良免疫刺激 (AIS).
- 不必要的免疫系统激活会阻碍早期的临床开发计划.
研究的目的:
- 在早期临床试验中引入用于管理AIS的标准化程序.
- 了解试验药品 (IMP) 的作用机制.
- 改善药物开发中的决策过程.
主要方法:
- 实施标准化血液采样程序.
- 测量AIS的特定生物标志物.
- 在早期临床试验中对AIS生物标志物的系统评估.
主要成果:
- 通过使用标准化程序,可以有效地管理AIS.
- 生物标志物分析提供了关于IMP作用机制的见解.
- 可以做出有关IMP再暴露和前期药物治疗的知情决定.
结论:
- 系统的AIS生物标志物评估提高了对病理生理机制的理解.
- 标准化的AIS评估可以使临床试验更有效,更具信息性.
- 这种方法可以防止有前途的候选药物的过早停药.
更多相关视频
14:01Human In Vitro Suppression as Screening Tool for the Recognition of an Early State of Immune Imbalance
Published on: July 22, 2011
15.0K
11:34A Simple and Efficient Method for Testing Immunomodulatory Agents for Generation of Tolerogenic Dendritic Cells from Human CD14+ Monocytes
Published on: April 11, 2025
795
相关概念视频
Cell-mediated Immune Responses
83.5K
Overview
83.5K
Types of Biopharmaceutical Studies: Controlled and Non-Controlled Approaches
407
Biopharmaceutical studies constitute a vital field aiming to enhance drug delivery methods and refine therapeutic approaches, drawing upon diverse interdisciplinary knowledge. In research methodologies, the choice between controlled and non-controlled studies significantly influences the study's reliability and accuracy.
Non-controlled studies, commonly employed for initial exploration, lack a control group, rendering them susceptible to biases and external influences. In contrast,...
Non-controlled studies, commonly employed for initial exploration, lack a control group, rendering them susceptible to biases and external influences. In contrast,...
407
